FSD Pharma

Quantum BioPharma develops novel therapies for neurological and inflammatory disorders. Its pharmaceutical asset, Lucid-MS, is a patented neuroprotective compound in Phase 1 clinical trials for Multiple Sclerosis, targeting myelin degradation. The company also offers 'unbuzzd', a functional beverage for mental clarity and detoxification post-alcohol consumption.

FSD Pharma Inc., founded in 2018 by Zeeshan Saeed and Anthony Durkacz, initially focused on cannabis cultivation. A strategic transition redirected efforts to biopharmaceutical research and development, recognizing unmet needs in neurodegenerative and inflammatory diseases. This evolution formed its current identity as Quantum BioPharma.

Quantum BioPharma primarily serves patients with severe neurological conditions like Multiple Sclerosis through its developing drug candidates. Its 'unbuzzd' product caters to consumers seeking wellness support after social alcohol use. The company’s vision is to become a leading biopharmaceutical firm, improving patient quality of life with advanced solutions for brain and systemic inflammatory conditions.